Standardized research and clinical efficacy evaluation of treatment of interstitial lung disease based on lung-collateral theory

Phase 1

• Conditions: interstitial lung disease

• Registration Number: ITMCTR2000003785
• Lead Sponsor: Shanghai Pulmonary Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the western medicine diagnosis of the disease;
2. Meet the TCM diagnosis and syndrome differentiation standards of this disease;
3. The patient voluntarily accepted the treatment and signed the informed consent.

Exclusion Criteria

1. Age> 80 years old;
2. Combined with tuberculosis, fungus, tumor, etc. and other primary lung diseases;
3. Patients with severe complications of other diseases such as cardiovascular, urinary, digestive, hematopoietic, endocrine and metabolic systems, liver and kidney insufficiency, and mental illness;
4. Pregnant or lactating women and those who are known to be allergic to the components of this medicine;
5. Those who fail to use the prescribed drugs and follow the doctor's advice, cannot judge the curative effect or whose clinical data is incomplete and affect the judgment;
6. Participating in other drug clinical trials.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HRCT change point;PaO2;symptom score;lung function;

Secondary Outcome Measures

Name	Time	Method
MRC score;the change score of ATAQ-IPF;